Loading
Promising academic cancer discoveries stall because nobody funds the expensive step from lab to first human trial. Build a shared public facility that does exactly that step, repeatedly.
The translational valley of death lies between validated preclinical results and a funded first-in-human study: manufacturing to clinical grade, toxicology, regulatory filing and early trial costs are beyond most academic groups and unattractive to investors before human data. NCI's NExT programme and some European infrastructures partially address this. The proposal is a purpose-built, publicly funded translation facility with in-house GMP manufacturing for biologics, cell products and small molecules, standing toxicology and regulatory teams, and a clinical unit, selecting projects competitively and retaining a public share of downstream value.
Shares Translational research: crossing the valley of death, The valley of death between lab and product.
Shares Funding follows fashion, not burden, National Cancer Institute (NIH).
Shares Translational research: crossing the valley of death, The valley of death between lab and product, National Cancer Institute (NIH).
Shares Translational research: crossing the valley of death, The valley of death between lab and product.
Shares Funding follows fashion, not burden, National Cancer Institute (NIH).
Shares Translational research: crossing the valley of death, The valley of death between lab and product.
Shares Translational research: crossing the valley of death, The valley of death between lab and product.
Shares The valley of death between lab and product, National Cancer Institute (NIH).